Starphama receives Frost & Sullivan leadership award
04 August, 2005 by Ruth BeranMelbourne drug developer Starpharma (ASX:SPL) has received the 2005 Frost & Sullivan Growth Strategy Leadership Award for the company's development of VivaGel and other polyvalent dendrimer-based products relating to the world nanobiotechnology market.
In brief: SciGen, Cryptome, Circadian, ChemGenex, Synchrotron
04 August, 2005 by Ruth BeranSciGen (ASX:SIE) executive vice-chairman and founder Saul Mashaal has been reappointed as CEO, a position he held until September 2001 when executive management of the company was transferred to Australia.
Victorian medical research institutes net $26m in state grants
04 August, 2005 by Ruth BeranThe Victorian government has pledged $26.6 million in infrastructure funding to 17 independent medical research institutes in the state.
Geelong biotech cluster receives $50,000 grant
04 August, 2005 by Ruth BeranThe Geelong Region Biotechnology Cluster Project has received a $50,000 Regional Innovation Clusters Program grant from the Victorian government to support its growth.
Biotech summit highlights sector's strong voice
02 August, 2005 by Helen SchullerPartnering, collaboration and communication were keenly discussed at the 3rd Australian Biotechnology Summit, held in Sydney last week. Australian of the Year and Clinical Cell Culture (C3) co-founder Fiona Wood led the charge, calling for a solution driven biotech industry.
Biotech financial results
01 August, 2005 by Helen SchullerResults in Brief: Vertex, Varian, Watson, Chiron, Alcon, Eyetech, Elan, NicOx, MorphoSys, Actelion, AstraZeneca, Shire, GSK, Bristol-Myers Squibb, QLT, Millennium, Celgene, Invitrogen, InterMune, Charles River, Ranbaxy, Takeda, Sankyo, Daiichi, Solvay
In brief: Peplin, Bone Medical, Probiomics, BioDiem
01 August, 2005 by Helen SchullerPeplin (ASX:PEP) has suspended its shares from the ASX's official quotation in the lead-up to an announcement.
Avastra discontinues Benz Stent project
01 August, 2005 by Ruth BeranSydney biomaterials company Avastra (ASX:AVS) has decided not to exercise its option to acquire the global rights to the Universitaetsklinikum Freiburg's Benz Stent technology.
Chemeq overcomes filtration issue, reveals CEO's salary package
01 August, 2005 by Ruth BeranThe recent installation of new equipment at antimicrobial specialist Chemeq's (ASX:CMQ) Rockingham manufacturing facility has overcome a filtration issue identified during commissioning of the plant.
Successful second Sunshine C-Pulse implant
01 August, 2005 by Graeme O'NeillThree days after the death of the first patient to be implanted with its C-Pulse heart-assist pump, Sunshine Heart (ASX:SHC) has announced that a second patient has been successfully implanted with the device in a two-hour operation at New Zealand's Auckland City Hospital.
Science Industry Action Agenda endorsed by government
29 July, 2005 by Susan WilliamsonThe federal government endorsed the recommendations of the Science Industry Action Agenda Measure by Measure report on July 12, giving the go ahead for the eight recommendations made in the report to be implemented.
In Brief: Bioprospect, pSivida, CollTech, Prana, BresaGen, Sirtex, ChemGenex
29 July, 2005 by Staff WritersSelwyn Snell has resigned as the CEO and a director of BioProspect (ASX:BPO), after three years with the company.
First US sale for USCOM
28 July, 2005 by Helen SchullerSydney-based devices company USCOM (ASX:UCM) has received its first US orders for its heart monitoring equipment.
Iatia achieves positive quarter
27 July, 2005 by Ruth BeranMicroscopy company Iatia (ASX:IAT) will achieve its first positive operating cash flow quarter for the period ended June 30.
CSL deal boosts GroPep profits
27 July, 2005 by Ruth BeranAdelaide-based GroPep's (ASX:GRO) net profit after tax for the 2004-2005 financial year has been boosted by a one-off tax benefit of AUD$3.4 million, and is now expected to be approximately $6.4 million compared with a previous estimate of $3 million.
